JP2023532917A5 - - Google Patents
Info
- Publication number
- JP2023532917A5 JP2023532917A5 JP2022581341A JP2022581341A JP2023532917A5 JP 2023532917 A5 JP2023532917 A5 JP 2023532917A5 JP 2022581341 A JP2022581341 A JP 2022581341A JP 2022581341 A JP2022581341 A JP 2022581341A JP 2023532917 A5 JP2023532917 A5 JP 2023532917A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- recombinant
- gene
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047978P | 2020-07-03 | 2020-07-03 | |
| US63/047,978 | 2020-07-03 | ||
| US202063114131P | 2020-11-16 | 2020-11-16 | |
| US63/114,131 | 2020-11-16 | ||
| PCT/US2021/039953 WO2022006309A1 (en) | 2020-07-03 | 2021-06-30 | Methods and compositions for editing the b2m locus in b cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023532917A JP2023532917A (ja) | 2023-08-01 |
| JP2023532917A5 true JP2023532917A5 (https=) | 2024-07-04 |
Family
ID=79315579
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022581341A Pending JP2023532917A (ja) | 2020-07-03 | 2021-06-30 | Ｂ細胞のｂ２ｍ遺伝子座を編集するための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4175651A4 (https=) |
| JP (1) | JP2023532917A (https=) |
| KR (1) | KR20230035048A (https=) |
| CN (1) | CN116033910A (https=) |
| AU (1) | AU2021300358A1 (https=) |
| BR (1) | BR112022026534A2 (https=) |
| CA (1) | CA3186620A1 (https=) |
| IL (1) | IL299491A (https=) |
| MX (1) | MX2022015788A (https=) |
| WO (1) | WO2022006309A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023187779A1 (en) * | 2022-03-28 | 2023-10-05 | Ramot At Tel-Aviv University Ltd. | Site-specific in vivo t cell engineering, systems, compositions and methods thereof |
| CA3261942A1 (en) * | 2022-08-01 | 2024-02-08 | Idexx Laboratories, Inc. | FRACTIONAL ABUNDANCE DOSES OF HUMAN MOUSE |
| WO2024220446A2 (en) * | 2023-04-17 | 2024-10-24 | Be Biopharma, Inc. | Engineered cell preparations for treatment of hemophilia |
| CN120866304A (zh) * | 2024-04-23 | 2025-10-31 | 南京奇迹生物科技有限公司 | 对b2m基因座的基因编辑方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3215623A4 (en) * | 2014-11-06 | 2018-09-26 | President and Fellows of Harvard College | Cells lacking b2m surface expression and methods for allogeneic administration of such cells |
| BR112018012235A2 (pt) * | 2015-12-18 | 2018-12-04 | Sangamo Therapeutics Inc | rompimento alvejado do receptor de células de mhc |
| CA3067914A1 (en) * | 2017-06-30 | 2019-01-03 | Cellectis | Cellular immunotherapy for repetitive administration |
| MX2020005235A (es) * | 2017-11-16 | 2020-08-24 | Mogam Inst Biomedical Res | Celula humana transformada y uso de la misma. |
| US12378572B2 (en) * | 2018-09-07 | 2025-08-05 | Crispr Therapeutics Ag | Universal donor cells |
| CN112805371B (zh) * | 2018-09-21 | 2025-10-31 | 克莱格医学有限公司 | 基于CRISPR/Cas系统对细胞进行基因编辑的方法 |
| UY38427A (es) * | 2018-10-26 | 2020-05-29 | Novartis Ag | Métodos y composiciones para terapia con células oculares |
-
2021
- 2021-06-30 BR BR112022026534A patent/BR112022026534A2/pt unknown
- 2021-06-30 KR KR1020237001885A patent/KR20230035048A/ko active Pending
- 2021-06-30 AU AU2021300358A patent/AU2021300358A1/en active Pending
- 2021-06-30 EP EP21832140.4A patent/EP4175651A4/en active Pending
- 2021-06-30 WO PCT/US2021/039953 patent/WO2022006309A1/en not_active Ceased
- 2021-06-30 MX MX2022015788A patent/MX2022015788A/es unknown
- 2021-06-30 IL IL299491A patent/IL299491A/en unknown
- 2021-06-30 CN CN202180047549.4A patent/CN116033910A/zh active Pending
- 2021-06-30 CA CA3186620A patent/CA3186620A1/en active Pending
- 2021-06-30 JP JP2022581341A patent/JP2023532917A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023532917A5 (https=) | ||
| JP7194230B2 (ja) | クローディン－１８．２－特異的免疫受容体およびｔ細胞エピトープ | |
| JP6538622B2 (ja) | ホモ二量体タンパク質コンストラクト | |
| EP3511413B1 (en) | Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule | |
| JP2020509780A5 (https=) | ||
| KR20230172630A (ko) | 종양 네오 항원성 펩타이드 | |
| JP2021168662A (ja) | 免疫グロブリンの産生増強 | |
| JP2024125354A (ja) | ペプチド－ｍｈｃ複合体に対する治療用抗体を生成するための遺伝子改変非ヒト動物、ならびにその作製方法および使用方法 | |
| US20150218260A1 (en) | Interleukin-2 fusion proteins and uses thereof | |
| RU2019119272A (ru) | Вирусная доставка неоантигенов | |
| JP2024519515A5 (https=) | ||
| KR20230172047A (ko) | 종양 신생항원 펩타이드 및 이의 용도 | |
| RS61387B2 (sr) | Gen optimizovanog faktora viii | |
| Kroczek et al. | Structure-function relationship of XCL1 used for in vivo targeting of antigen into XCR1+ dendritic cells | |
| JP2023532917A (ja) | Ｂ細胞のｂ２ｍ遺伝子座を編集するための方法および組成物 | |
| JP2023526587A (ja) | 改変型上皮成長因子受容体及び細胞追跡におけるその使用 | |
| TW201124535A (en) | SORF constructs and multiple gene expression | |
| Boulanger et al. | Absence of tapasin alters immunodominance against a lymphocytic choriomeningitis virus polytope | |
| Simpson et al. | FcγRIIB (CD32B) antibodies enhance immune responses through activating FcγRs | |
| CN1511163A (zh) | 抗体制备与筛选方法 | |
| KR20250021382A (ko) | 바이러스 펩티드 및 이의 용도 | |
| US12162925B2 (en) | DNA-encoded monoclonal antibodies targeting the Ebolavirus glycoprotein | |
| CN1194089C (zh) | 大胡蜂镇静肽前体基因及其编码的多肽和制备方法 | |
| KR20060135280A (ko) | 선천성 면역에 관여하는 트렘-2의 클로닝 | |
| EP4501954A1 (en) | A nucleic acid encoding a cd8 alpha beta co-receptor, cells and pharmaceutical compositions comprising the same |